Featured Research

from universities, journals, and other organizations

Merlin Tells When To Grow And When To Stop

Date:
April 17, 2001
Source:
Cold Spring Harbor Laboratory
Summary:
An international team of scientists lead by Dr. Peter Herrlich at the University of Karlsruhe in Germany has discovered how the tumor suppressor, merlin, functions. Mutations in merlin cause Neurofibromatosis type 2 (NF2), a common inherited disorder that features the predisposition to develop multiple benign tumors of the central nervous system.

An international team of scientists lead by Dr. Peter Herrlich at the University of Karlsruhe in Germany has discovered how the tumor suppressor, merlin, functions. Mutations in merlin cause Neurofibromatosis type 2 (NF2), a common inherited disorder that features the predisposition to develop multiple benign tumors of the central nervous system. Published in Genes & Development, this work delineates the pathway by which cells that are mutant in merlin become tumorigenic.

Cell density is one of several growth-limiting parameters. Normal cells proliferate until they occupy the space allotted to them, and stop proliferating once they contact other cells or a dense extracellular environment. Overcoming this contact growth inhibition is an integral aspect of cancer induction. Dr. Herrlich and colleagues have found that merlin is a key component of the mechanism by which a cell responds to contact inhibition.

Although previous studies have identified merlin as a negative regulator of cell growth, this paper is the first documentation of merlin’s specific role in the contact inhibition of growth. Under high cell density conditions, the extracellular portion of the cell membrane-spanning protein, CD44, binds to a specific component of the matrix that surrounds adjacent proliferating cells. Dr. Herrlich and colleagues have shown that once this occurs, merlin becomes desphosphorylated, and forms a tight bond with the intracellular portion of CD44. This activated form of merlin effectively blocks further cell proliferation.

The data presented in this paper has significant implications for the understanding of how merlin deficiency contributes to tumorigenesis. NF2 patients display multiple tumors derived from glial cells. This work suggests that because these glial cells lacked the merlin/CD44 growth regulatory switch, they were able to overcome contact growth inhibition. Although contact inhibition is only one form of cell growth regulation, the insight that Dr. Herrlich and colleagues have provided into the mechanism of contact growth inhibition will undoubtedly improve our understanding of cancer development.


Story Source:

The above story is based on materials provided by Cold Spring Harbor Laboratory. Note: Materials may be edited for content and length.


Cite This Page:

Cold Spring Harbor Laboratory. "Merlin Tells When To Grow And When To Stop." ScienceDaily. ScienceDaily, 17 April 2001. <www.sciencedaily.com/releases/2001/04/010415224232.htm>.
Cold Spring Harbor Laboratory. (2001, April 17). Merlin Tells When To Grow And When To Stop. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2001/04/010415224232.htm
Cold Spring Harbor Laboratory. "Merlin Tells When To Grow And When To Stop." ScienceDaily. www.sciencedaily.com/releases/2001/04/010415224232.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins